CN111700938A - A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst - Google Patents
A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst Download PDFInfo
- Publication number
- CN111700938A CN111700938A CN202010791502.6A CN202010791502A CN111700938A CN 111700938 A CN111700938 A CN 111700938A CN 202010791502 A CN202010791502 A CN 202010791502A CN 111700938 A CN111700938 A CN 111700938A
- Authority
- CN
- China
- Prior art keywords
- radix
- traditional chinese
- chinese medicine
- medicine composition
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 206010033635 Pancreatic pseudocyst Diseases 0.000 title claims abstract description 9
- 206010033645 Pancreatitis Diseases 0.000 title claims description 29
- 239000003814 drug Substances 0.000 claims abstract description 150
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 59
- 239000000126 substance Substances 0.000 claims abstract description 56
- 241000218176 Corydalis Species 0.000 claims abstract description 28
- 230000002195 synergetic effect Effects 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 20
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 13
- 239000010446 mirabilite Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 241000202726 Bupleurum Species 0.000 claims abstract description 9
- 239000000052 vinegar Substances 0.000 claims abstract description 8
- 235000021419 vinegar Nutrition 0.000 claims abstract description 8
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 6
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 6
- 241000207929 Scutellaria Species 0.000 claims abstract description 6
- 244000272264 Saussurea lappa Species 0.000 claims abstract description 3
- 235000006784 Saussurea lappa Nutrition 0.000 claims abstract description 3
- 244000111489 Gardenia augusta Species 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 46
- 238000001914 filtration Methods 0.000 claims description 39
- 239000000706 filtrate Substances 0.000 claims description 37
- 210000000496 pancreas Anatomy 0.000 claims description 35
- 238000002791 soaking Methods 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 30
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 22
- 201000003229 acute pancreatitis Diseases 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 238000007873 sieving Methods 0.000 claims description 19
- 238000010298 pulverizing process Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 13
- 229930064664 L-arginine Natural products 0.000 claims description 13
- 235000014852 L-arginine Nutrition 0.000 claims description 13
- 241000219061 Rheum Species 0.000 claims description 13
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 12
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 238000007605 air drying Methods 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 4
- 206010056658 Pseudocyst Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 240000004980 Rheum officinale Species 0.000 claims description 2
- 235000008081 Rheum officinale Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 238000007710 freezing Methods 0.000 abstract description 3
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 37
- 229940079593 drug Drugs 0.000 description 36
- 241000700159 Rattus Species 0.000 description 35
- 238000012360 testing method Methods 0.000 description 27
- 230000001575 pathological effect Effects 0.000 description 19
- 210000000277 pancreatic duct Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000000265 leukocyte Anatomy 0.000 description 14
- 230000036760 body temperature Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 210000000232 gallbladder Anatomy 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000004923 pancreatic tissue Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 241000157835 Gardenia Species 0.000 description 5
- 206010028665 Myxoedema Diseases 0.000 description 5
- 240000004534 Scutellaria baicalensis Species 0.000 description 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 210000003371 toe Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 208000003786 myxedema Diseases 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- GGLZPLKKBSSKCX-UHFFFAOYSA-N S-ethylhomocysteine Chemical compound CCSCCC(N)C(O)=O GGLZPLKKBSSKCX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000007119 pathological manifestation Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 1
- 206010043417 Therapeutic response unexpected Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating acute and chronic pancreatitis and pancreatic pseudocyst, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition comprises effective components and medically acceptable auxiliary materials, wherein the effective components comprise: 320g of bupleurum, 100 g of scutellaria, 150 g of white peony, 300g of costus root, 150 g of vinegar rhizoma corydalis, 350g of gardenia, 400g of rhubarb and 100 g of mirabilite; a certain amount of synergistic components are added into the traditional Chinese medicine composition, and the weight of the synergistic components is controlled to be 1-3% of the weight of the effective components, so that the medicine absorption can be effectively promoted, and the treatment effect can be effectively improved; in the preparation process, the mass-volume ratio of 1 g: 1mL of water is soaked for a certain time, and a quick-freezing and instant-dissolving mode is adopted, so that the cell structure can be damaged, the dissolution of effective substances is increased, and the utilization rate of the medicine is improved.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating acute pancreatitis, chronic pancreatitis and pancreatic pseudocyst.
Background
Acute pancreatitis is an inflammatory reaction of self digestion, edema, hemorrhage and even necrosis of pancreatic tissues caused by pancreatic enzymes activated in pancreas due to various causes, and is a common digestive system disease. According to the onset part and clinical characteristics of acute pancreatitis, it can be classified into "splenic cardialgia" and "pancreatic fever". Clinically, it is characterized by acute epigastric pain, nausea, vomiting, fever and elevated blood and urine amylase. Mild and moderate acute pancreatitis is a self-limiting disease, the prognosis is good after active treatment, but 15-20% of the mild and moderate acute pancreatitis is severe acute pancreatitis, the incidence of the disease is acute, the disease condition is severe, the change is rapid, the fatality rate is as high as 36-50%, and the method is a great challenge in clinical diagnosis and treatment. Acute pancreatitis, especially severe acute pancreatitis, has the characteristics of acute onset, severe organ involvement, rapid disease progression and the like. At an early stage, patients are very likely to develop systemic capillary leak syndrome due to SIRS, followed by organ insufficiency or failure, and even death.
At present, the treatment of acute pancreatitis forms a non-operative treatment system mainly based on early support treatment, namely, early fluid resuscitation, maintenance and replacement of organ functions, antibiotic use and nutritional support. The university of Dalian medical sciences affiliated with the first hospital developed a combined traditional and western therapy for acute pancreatitis as early as the 50 s of the 20 th century. Based on traditional meridians, the pancreas-clearing decoction is prepared by Cao Zhong and professor after Qingming imperial doctor, Chengrong & palace professor in reputations at home, and the like. On the basis of the conventional western medicine treatment, the clear pancreas soup is adopted for treatment, and a good clinical effect is obtained. Long-term clinical and basic experiments prove that the formula of the clear pancreas decoction is matched to be used on the basis of conventional western medicine treatment, so that the effects of maintaining internal environment stability, improving gastrointestinal motility and inhibiting inflammatory injury to maintain important organ functions and reduce organ failure can be achieved. Thereby achieving the aims of promoting the recovery of organ functions, reducing infection and local complications, shortening the hospitalization time and reducing the fatality rate.
According to the traditional Chinese medicine, the pancreas is directly communicated with the shaoyang gallbladder through a pipeline, and the common opening or the common channel can be used as an anatomical basis for the mutual association of pancreatic diseases and biliary tract diseases. The triple energizer meridian of hand shaoyang enters the deficient basin, has a smell of mutton, falls into the pericardium and the lower diaphragm, and belongs to the triple energizer. The shaoyang meridians run along the chest and abdomen symmetrically on both sides of the body. The left gallbladder meridian runs along the lower middle part of the chest, runs through the diaphragm, connects with the liver, and runs through the hypochondrium, where it must pass through the pancreas. The digestive juice secreted by pancreas is discharged from pancreatic duct into intestinal tract, and is discharged together with bile of shaoyang gallbladder under the action of liver qi, and then injected into intestine. The Shaoyang gallbladder organs and the pancreas are anatomically connected by pipelines in the traditional Chinese medicine, the Shaoyang channels and the pancreas channels are connected along the circulation, and the pancreas and the Shaoyang physiological functions are similar, so the pancreas and the Shaoyang gallbladder organs are closely related physiologically.
In Shang Han Lun, the symptoms of Dachaihu decoction such as vomiting, urgent heart, depression, restlessness, fever and constipation are similar to those of vomiting, epigastric pain, fever and constipation in the early stage of acute pancreatitis, and the pathogenesis of both is the combination of shaoyang and yangming syndromes. The pathogenesis of the disease is mainly caused by overeating, fat, sweet, thick and greasy food, patients mostly have constitutions of yang heat with internal exuberance, pathogenic qi invades shaoyang, the pivot is unfavorable, qi stagnation is transformed from heat, and the clinical manifestation and pathogenesis evolution mainly comprise that shaoyang gallbladder stagnation heat is in the interior. Meanwhile, pancreatin is activated in the pancreatic duct, which is a necessary condition for causing local inflammation of pancreas, so that pancreatin activation of acute pancreatitis is similar to pathogenesis evolution of stagnation of shaoyang heat in the interior, blazing the interior and exterior, and obstruction of qi in the yangming fu-organs, and treatment is to clear shaoyang, promote qi circulation and clear fu-organs. The prescription takes radix bupleuri and rhubarb as monarch drugs for soothing the liver and regulating qi, and clearing the hollow viscera and descending the turbid as the monarch drugs; the auxiliary materials are scutellaria baicalensis and gardenia, and the auxiliary materials are used for clearing heat, benefiting gallbladder, purging heat and removing toxicity; wherein the bupleurum and the scutellaria baicalensis harmonize Shaoyang; adjuvant drugs including Natrii sulfas, radix Paeoniae alba, and rhizoma corydalis, with effects of clearing heat, relaxing bowels, and relieving pain; the guiding drug is costustoot for regulating qi and activating spleen, and the drug property is harmonized; the medicines are used together to play the efficacies of dispersing stagnated liver qi, clearing away heat and toxic material, and dredging the interior and eliminating the pathogenic factors.
At present, a good-effect medicine for treating acute pancreatitis is not available, and compared with western medicines, the traditional Chinese medicine has the advantages of generally better effect, small toxic and side effects, suitability for long-term administration and low cost. In order to be more convenient for patients to take, the formulation of the clear pancreas decoction is improved to prepare the traditional Chinese medicine composition. The traditional Chinese medicine composition developed on the basis of clinical and experimental tests for 60 years is proved to be safe and effective, has no obvious toxic or side effect, and has higher clinical practical value and wide market prospect through serum pharmacology and toxicology experiments.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating acute and chronic pancreatitis and pancreatic pseudocyst, which can be used together with a conventional western medicine treatment to achieve the effects of promoting organ function recovery, reducing infection and local complications, shortening hospitalization time and reducing fatality rate.
The technical solution of the invention for realizing the above purpose is as follows:
a Chinese medicinal composition for treating acute pancreatitis, chronic pancreatitis and pancreatic pseudocyst comprises effective components and medically acceptable adjuvants.
The effective components comprise: 320g of bupleurum, 100 g of scutellaria, 150 g of white peony, 300g of costus root, 150 g of vinegar rhizoma corydalis, 350g of gardenia, 400g of rhubarb and 100 g of mirabilite;
preferably, the effective components comprise: 200-300g of bupleurum, 120-200g of scutellaria, 180-250g of white peony root, 180-250g of costustoot, 150-250g of vinegar rhizoma corydalis, 220-320g of gardenia, 300-380g of rhubarb and 120-180g of mirabilite.
Still preferably, the active ingredients include: 300g of bupleurum root, 200g of scutellaria root, 150 g of white peony root, 300g of costustoot, 100 g of vinegar rhizoma corydalis, 350g of gardenia, 400g of rhubarb and 100 g of mirabilite.
In a preferred embodiment, the active ingredients comprise: 250g of radix bupleuri, 200g of scutellaria baicalensis, 250g of radix paeoniae alba, 250g of elecampane, 250g of vinegar rhizoma corydalis, 250g of fructus gardeniae, 330g of rheum officinale and 167g of mirabilite.
The traditional Chinese medicine composition also contains synergistic components, and the weight of the synergistic components is 1-3% of the effective components.
The synergistic component is one or more of L-arginine, vitamin E and menthol;
preferably, the synergistic component is one or more of L-arginine and vitamin E;
further preferably, the synergistic components are L-arginine and vitamin E;
still further preferably, the synergistic components are vitamin E and L-arginine in a weight ratio of 2-5: 1;
still more preferably, the synergistic components are vitamin E and L-arginine in a weight ratio of 3: 1.
The weight of the synergistic component is 1-3% of the effective component; preferably 1, 2 or 3%, more preferably 2%.
The medically acceptable auxiliary materials are one or more of a filling agent, a wetting agent, an adhesive, a disintegrating agent and a lubricating agent.
The filler is one or more of dextrin, starch, lactose and sucrose.
The adhesive is one or more of powdered sugar, hydroxypropyl methylcellulose, methylcellulose and carboxymethyl cellulose.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
(1) removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae, and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving to obtain fine powder; mixing fine powders of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, and soaking under ultrasonic treatment for one time, two times, three times and four times to obtain a mixed solution of the soaking material and the filtrate;
(2) pulverizing Natrii sulfas with a pulverizer, and sieving to obtain fine powder;
(3) decocting the soaked materials in the step (1) with water, and filtering to obtain medicine residue 1 and an extracted medicine liquid 1;
(4) adding water into the Chinese medicine residue 1 in the step (3) again, boiling, adding rhubarb powder, decocting, and filtering to obtain an extracted liquid medicine 2;
(5) combining the combined solution obtained in the steps (1), (3) and (4), the extracted liquid medicine 1 and the extracted liquid medicine 2, and concentrating the mixture to thick paste with the relative density of 1.30-1.33 (50-60 ℃);
(6) adding auxiliary materials and synergistic components into the thick paste obtained in the step (5), uniformly mixing, and drying to obtain dry paste;
(7) mixing the dry paste obtained in step (6) with the mirabilite fine powder obtained in step (2), pulverizing into fine powder, sieving, adding adjuvants, mixing, granulating with 80% ethanol, drying (60-80 deg.C), grading, and packaging to obtain the pharmaceutical composition;
the step (1) comprises the following specific steps:
removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae, and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powders of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 10-20 deg.C for 3 hr under ultrasonic condition, and filtering to obtain filtrate 1 and soaked substance 1; quickly placing the soaked substance 1 in water of 70-80 ℃ for soaking for 3 hours, and filtering to obtain filtrate 2 and soaked substance 2; rapidly soaking the soaked substance 2 in 10-20 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; rapidly soaking the soaked substance 3 at 70-80 deg.C for 1 hr, and filtering to obtain filtrate 4 and soaked substance 4; mixing the filtrates 1-4 to obtain mixed solution;
the mass ratio of the volume of the added water to the fine medicine powder, the soaked substance 1, the soaked substance 2 and the soaked substance 3 is 1mL:1 g.
Preferably, the specific steps in the step (1) are as follows:
removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powder of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 15 deg.C for 3 hr under ultrasonic treatment, filtering to obtain filtrate 1 and soak 1, rapidly soaking soak 1 in 80 deg.C water for 3 hr, and filtering to obtain filtrate 2 and soak 2; rapidly soaking the soaked substance 2 in 10 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; rapidly soaking the soaked substance 3 in 75 deg.C water for 1 hr, filtering to obtain filtrate 4 and soaked substance 4, and mixing filtrates 1-4 to obtain mixed solution;
the mass ratio of the volume of the added water to the fine medicine powder, the soaked substance 1, the soaked substance 2 and the soaked substance 3 is 1mL:1 g.
The step (2) is to sieve the mixture through a 200-mesh sieve.
The step (3) is to add 8 to 10 times of water, decoct for 1 to 2 hours, filter and obtain the extract liquid 1.
The step (4) is to add 6 to 8 times of water, add rhubarb after boiling, decoct for 1 hour, filter and obtain the extraction liquid medicine 2.
The preparation method of the traditional Chinese medicine composition specifically comprises the following steps:
(1) removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae, and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powders of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 10-20 deg.C for 3 hr under ultrasonic condition, and filtering to obtain filtrate 1 and soaked substance 1; quickly placing the soaked substance 1 in water of 70-80 ℃ for soaking for 3 hours, and filtering to obtain filtrate 2 and soaked substance 2; rapidly soaking the soaked substance 2 in 10-20 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; rapidly soaking the soaked substance 3 at 70-80 deg.C for 1 hr, and filtering to obtain filtrate 4 and soaked substance 4; mixing the filtrates 1-4 to obtain mixed solution;
the volume of the added water and the mass ratio of the fine medicine powder, the soak 1, the soak 2 and the soak 3 are all 1mL:1 g;
(2) pulverizing Natrii sulfas with a pulverizer, and sieving with 200 mesh sieve to obtain fine powder;
(3) adding 8-10 times of water into the soaked matter 4 in the step (1), decocting for 1-2 hours, and filtering to obtain medicine residue 1 and an extracted medicine liquid 1;
(4) adding 6-8 times of water into the Chinese medicine residue 1 in the step (3), boiling, adding rhubarb powder, decocting for 1 hour, and filtering to obtain an extracted liquid medicine 2;
(5) combining the combined solution obtained in the steps (1), (3) and (4), the extracted liquid medicine 1 and the extracted liquid medicine 2, and concentrating the mixture to thick paste with the relative density of 1.30-1.33 (50-60 ℃);
(6) adding auxiliary materials and synergistic components into the thick paste obtained in the step (5), uniformly mixing, and drying at the temperature of below 80 ℃ to obtain dry paste;
(7) and (3) mixing the dry paste obtained in the step (6) with the mirabilite fine powder obtained in the step (2), crushing into fine powder, sieving with a 100-mesh sieve, adding auxiliary materials, uniformly mixing, preparing into granules by using 80% ethanol, drying (60-80 ℃), grading, and packaging to obtain the pharmaceutical composition.
The invention also provides application of the traditional Chinese medicine composition in preparing a medicine composition for treating acute pancreatitis, chronic pancreatitis and pancreatic pseudocyst.
Compared with the prior art, the invention has the beneficial effects that:
(1) the pharmaceutical composition disclosed by the invention takes radix bupleuri and rhubarb as monarch drugs for soothing liver and regulating qi, and clearing hollow viscera and descending turbid as monarch drugs; the auxiliary materials are scutellaria baicalensis and gardenia, and the auxiliary materials are used for clearing heat, benefiting gallbladder, purging heat and removing toxicity; wherein the bupleurum and the scutellaria baicalensis harmonize Shaoyang; adjuvant drugs including Natrii sulfas, radix Paeoniae alba, and rhizoma corydalis, with effects of clearing heat, relaxing bowels, and relieving pain; the guiding drug is costustoot for regulating qi and activating spleen, and the drug property is harmonized; the medicines are used together to play the efficacies of dispersing stagnated liver qi, clearing away heat and toxic material, and dredging the interior and eliminating the pathogenic factors. Is mainly used for treating diseases such as acute pancreatitis, chronic pancreatitis, pancreatic pseudocyst, etc.;
(2) according to the invention, a certain amount of synergistic components are added into the pharmaceutical composition, so that the drug absorption can be effectively promoted, and the treatment effect can be effectively improved; the weight of the synergistic component is controlled to be 1-3% of the effective component, so that the content of the effective component can be ensured, and the release of the medicinal component can be effectively improved;
(3) before the preparation process, the preparation method adopts water with the mass volume of 1:1 to soak for a certain time, and adopts a quick-freezing instant mode (namely, the temperature is reduced to about 10-20 ℃ in a certain short time, and the temperature is increased to about 70-80 ℃ in a certain short time), the preparation method is repeated for several times, the quick-freezing instant mode is utilized to destroy the cell structure, increase the dissolution of effective substances and improve the utilization rate of the medicine;
(4) the ultrasonic extraction is combined in the process of soaking and extracting the medicine, so that the extraction efficiency is increased, and the medicine effect is further improved.
Drawings
FIG. 1 is a pathological picture of rat pancreatitis;
FIG. 2 is a pathological picture of mouse pancreatitis;
wherein a1 is a pathological picture of the pancreas of a blank control group rat; b1 is a pathological picture of rat pancreas in a model group; c1 is a pathological picture of rat pancreas of the positive drug group; d1 is a pathological picture of the pancreas of rats in the high dose group; e1 is a pathological picture of the pancreas of rats in the middle dose group; f1 is pathological picture of rat pancreas in low dose group;
a2 is a pathological image of the pancreas of a blank control group mouse; b2 is a pathological image of the pancreas of a mouse in a model group; c2 is a positive drug group mouse pancreas pathological picture; d2 is a pathological picture of the pancreas of mice in the high-dose group; e2 is a pathological image of the pancreas of the mice in the middle dose group; f2 is a pathological picture of the pancreas of mice in a low dose group.
Detailed Description
The invention is further described below with reference to specific embodiments.
Examples 1 to 4A Chinese medicinal composition for treating acute pancreatitis, chronic pancreatitis and pseudocyst of pancreas
The preparation method of the traditional Chinese medicine composition specifically comprises the following steps:
(1) removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae, and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powders of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 10 deg.C for 3 hr under ultrasonic condition, and filtering to obtain filtrate 1 and soaked substance 1; quickly placing the soaked substance 1 in water of 80 ℃ for soaking for 3 hours, and filtering to obtain filtrate 2 and a soaked substance 2; rapidly soaking the soaked substance 2 in 10 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; quickly soaking the soaked substance 3 at 70 ℃ for 1 hour, and filtering to obtain filtrate 4 and soaked substance 4; mixing the filtrates 1-4 to obtain mixed solution;
the volume of the added water and the mass ratio of the fine medicine powder, the soak 1, the soak 2 and the soak 3 are all 1mL:1 g;
(2) pulverizing Natrii sulfas with a pulverizer, and sieving with 200 mesh sieve to obtain fine powder;
(3) adding 8 times of water into the soaked matter 4 in the step (1), decocting for 2 hours, and filtering to obtain filter residue 1 and extraction liquid medicine 1;
(4) adding 6 times of water into the filter residue 1 in the step (3), boiling, adding rhubarb powder, decocting for 1 hour, and filtering to obtain an extracted liquid medicine 2;
(5) combining the combined solution obtained in the steps (1), (3) and (4), the extracted liquid medicine 1 and the extracted liquid medicine 2, and concentrating the mixture to thick paste with the relative density of 1.30-1.33 (50-60 ℃);
(6) adding auxiliary materials and synergistic components into the thick paste obtained in the step (5), uniformly mixing, and drying at the temperature of below 80 ℃ to obtain dry paste;
(7) and (3) mixing the dry paste obtained in the step (6) with the mirabilite fine powder obtained in the step (2), crushing into fine powder, sieving with a 100-mesh sieve, adding auxiliary materials, uniformly mixing, preparing into granules by using 80% ethanol, drying (60-80 ℃), grading, and packaging to obtain the pharmaceutical composition.
Examples 5 to 7A Chinese medicinal composition for treating acute pancreatitis, chronic pancreatitis and pseudocyst of pancreas
The preparation method of the traditional Chinese medicine composition specifically comprises the following steps:
(1) removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powder of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 15 deg.C for 3 hr under ultrasonic treatment, filtering to obtain filtrate 1 and soak 1, rapidly soaking soak 1 in 80 deg.C water for 3 hr, and filtering to obtain filtrate 2 and soak 2; rapidly soaking the soaked substance 2 in 10 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; rapidly soaking the soaked substance 3 in 75 deg.C water for 1 hr, filtering to obtain filtrate 4 and soaked substance 4, and mixing filtrates 1-4 to obtain mixed solution;
the mass ratio of the volume of the added water to the fine medicine powder, the soak 1, the soak 2 and the soak 3 is 1mL:1 g;
(2) pulverizing Natrii sulfas with a pulverizer, and sieving with 200 mesh sieve to obtain fine powder;
(3) adding 10 times of water into the soaked matter 4 in the step (1), decocting for 2 hours, and filtering to obtain filter residue 1 and extraction liquid medicine 1;
(4) adding 8 times of water into the filter residue 1 in the step (3), boiling, adding rhubarb powder, decocting for 1 hour, and filtering to obtain an extract liquid 2;
(5) combining the combined solution obtained in the steps (1), (3) and (4), the extracted liquid medicine 1 and the extracted liquid medicine 2, and concentrating the mixture to thick paste with the relative density of 1.30-1.33 (50-60 ℃);
(6) adding auxiliary materials and synergistic components into the thick paste obtained in the step (5), uniformly mixing, and drying at the temperature of below 80 ℃ to obtain dry paste;
(7) and (3) mixing the dry paste obtained in the step (6) with the mirabilite fine powder obtained in the step (2), crushing into fine powder, sieving with a 100-mesh sieve, adding auxiliary materials, uniformly mixing, preparing into granules by using 80% ethanol, drying (60-80 ℃), grading, and packaging to obtain the pharmaceutical composition.
Comparative example 1
The difference from example 7 is that:
the synergistic components are vitamin E and L-arginine with the mass ratio of 1:1, namely 19.47g of L-arginine and 19.47g of vitamin E, and other steps and operations are the same as those of the example 7.
Comparative example 2
The difference from example 7 is that:
the synergistic components are vitamin E and L-arginine with the mass ratio of 7:1, namely vitamin E34.0725 g and L-arginine 4.8675g, and other steps and operations are the same as those of the example 7.
Comparative example 3
The difference from example 7 is that:
the step (1) is as follows:
removing impurities of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae and radix et rhizoma Rhei, cleaning, air drying, pulverizing, sieving with 200 mesh sieve to obtain fine powder, soaking the fine powder of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae in 50 deg.C water for 5 hr under ultrasonic treatment, and filtering to obtain filtrate 1 and soaked substance 1;
the mass ratio of the volume of the added water to the fine medicine powder and the soaked substance 1 is 1mL to 1 g.
Test examples
1. Acute toxicity test:
the purpose is as follows: no LD could be detected in preliminary experiments50On the basis of the method, the maximum tolerance dose per day is improved to evaluate the acute toxicity of the tested medicament and study the safety of clinical medication.
The method comprises the following steps: taking 40 healthy mice, half of each male and female, weighing 20 +/-2 g, and 20: 00 begins, fasting does not prohibit water. Mice were randomized into two groups of 20 mice per group, dosed (example 7) and blank control. The prepared traditional Chinese medicine composition water solution is administered to the administration group by gavage with 0.4mL/10g each time, the administration is repeated once every 3 hours with the same dosage and method, the administration is carried out for three times continuously, and the blank control group is administered with the same volume of normal saline in the same time. After administration, the mice were placed in a mouse box and fed in a single cage, and the activity, feed intake, poisoning manifestation and death number of the two groups of mice were observed for 7 days continuously.
As a result: after administration, both groups of mice had normal activity, coordinated movement, no significant inhibition or excitation of central nervous system reactions, normal diet, no anorexia, diarrhea, writhing reactions and other digestive system symptoms, and no death of one animal and progressive weight gain were observed for 7 days, with the results shown in Table 1.
TABLE 1 Chinese medicinal composition mouse acute toxicity Limit test (
n＝20)
And (4) conclusion: the maximum tolerance dose of the traditional Chinese medicine composition for intragastric administration of mice is 120g/kg of body weight, which is equivalent to 240 times of the dose of clinical adults, and no obvious toxic reaction is seen, which indicates that the traditional Chinese medicine is safe for clinical administration.
2. The main pharmacodynamic tests of the traditional Chinese medicine composition related to the functional indications are as follows:
the purpose is as follows: the main pharmacodynamic action of the traditional Chinese medicine composition related to the functional indications is observed.
(1) Influence of traditional Chinese medicine composition on chronic pancreatitis of rat caused by DL-ethionine
1) Effect on body temperature and blood leukocyte count
A rat chronic pancreatitis model caused by intraperitoneal injection of DL-ethionine is adopted, the influence of the traditional Chinese medicine composition on the body temperature and the blood leukocyte count of a rat with chronic pancreatitis is observed, healthy rats are taken, the number of the rats is 150 in each half, each group is 10, and the experimental rats are 20: 00 begins, fasting does not prohibit water. Experiments were performed using the medium doses of the Chinese medicinal compositions prepared in examples 1 to 6 and comparative examples 1 to 3, and experiments were performed using the low, medium and high dose groups of the Chinese medicinal composition prepared in example 7, as shown in table 2;
TABLE 2 Chinese medicinal composition for DInfluence of L-ethionine on body temperature and blood leukocytes in rat chronic pancreatitis: (
n＝10)
P <0.05, P <0.01, P <0.001 and model group comparisons
As can be seen from the data in Table 2 above, the body temperature and white blood cells were somewhat reduced after the administration of the doses in the Chinese medicinal compositions prepared in examples 1 to 6, but the body temperature and white blood cells were not reduced to a greater extent after the administration of the dose group (1.6g/kg) and the high dose group (3.2g/kg) in the Chinese medicinal composition prepared in example 7. While comparative examples 1 to 3 changed the mass ratio of the synergistic components, the body temperature and leukocytes were all reduced after administration, but the change was not great as compared with the model group.
2) Pathological manifestations
At the end of the experiment, animals were sacrificed, pancreata were dissected from the blank control group, model group, positive drug group, and high, medium, and low dose group of example 7, fixed with 10% formalin, subjected to pathological examination, and the rat pancreatitis condition was observed.
The pathological manifestations are shown in figure 1.
FIG. a1 is a blank control: the outline of the pancreatic lobules is clear and evenly distributed, pancreatic ducts and blood vessels can be seen in the connective tissues among the lobules, no mucous edema exists, acinar cells are in a cone shape, the cytoplasm is full, cell nucleuses are round and are positioned at the base part and are regularly arranged, and pancreatic tissues can be seen to be scattered in a small amount of inflammatory cells.
FIG. b1 is a model set: it is seen that there is a large amount of inflammatory cells infiltrating the pancreatic duct and the area around the lobules, the acinus is in diffuse sheet mucoid edema, the acinus cells become large, the pancreatic duct and the acinus morphological structure are damaged in different degrees, and the pancreatic interstitium has collagen fiber tissue hyperplasia.
The attached figure c1 is a positive drug group: the morphological structure of the pancreatic tissue is basically normal, the myxoedema is basically recovered, and the cells are basically cone-shaped; small numbers of scattered inflammatory cells were still visible in the intra-islet, lobular and pancreatic ductal pancreas and surrounding areas.
Figure d1 shows the high dose group: the morphological structure of the pancreatic tissue is close to normal, acinar sheet myxedema is basically recovered, and cells are basically cone-shaped; however, small amounts of scattered inflammatory cells, sporadic collagenous fibers in the lobules and interstitium are still visible in the pancreas islet, lobules of the gland, pancreas ductus and surrounding areas.
The accompanying figure e1 is for the medium dose group: the morphological structure of the lobules and the pancreatic ducts of the pancreas is basically improved, inflammatory cells in the peripheral area are obviously reduced, the lower dose group of acinar lamellar myxedema is changed, a small amount of inflammatory cells are still visible in the pancreatic islets, and the hyperplasia of collagen fibers in the lobules and the interstitial tissues is obviously reduced.
The accompanying drawing f1 is for the low dose group: inflammatory cells in the area around pancreatic ducts and lobules are reduced, acinar sheet myxedema is relieved, pancreatic ducts and acinar structures are restored, and hyperplastic collagen fibers can still be seen in the lobules and interstitium.
The pathological examination results of rat pancreas show that the traditional Chinese medicine composition has the effect of resisting chronic pancreatitis of rats to different degrees.
(2) Antipyretic effect of traditional Chinese medicine composition on rat fever caused by 2, 4-dinitrophenol
Taking 150 healthy rats with half of each male and female, the body weight of 200 +/-20 g, and 20: 00 begins, fasting does not prohibit water. During the test, the mice are randomly divided into six groups, namely a blank control group, a model group, a middle dose group in examples 1-6, a middle dose group in comparative examples 1-3, a high dose group (3.2g/kg) in example 7, a middle dose group (1.6g/kg), a low dose group (0.8g/kg) and a positive drug group (1.6g/kg), and each group comprises 10 mice.
Each group of rats was gavaged with the test drug twice daily for 3 consecutive days. Wherein the medium dose is equivalent to the clinical treatment dose, and the blank control group is administered with the same volume of physiological saline. Except for the blank control group, each group was injected subcutaneously with 2, 4-dinitrophenol 25mg/kg 1 hour after the last administration. The body temperature of rats was measured 1, 2, 4h after injection, and blood leukocytes were measured at 4 hours after blood withdrawal. The test results are shown in tables 3-4.
TABLE 3 Effect of Chinese medicinal composition on body temperature of rats pyrogenically induced by dinitrophenol: (
n＝10)
P <0.05, P <0.01, P <0.001 and model group comparisons
TABLE 4 Effect of Chinese medicinal composition on the blood leukocytes of rats pyrogenically produced by dinitrophenol: (
n＝10)
P <0.05, P <0.01, P <0.001 and model group comparisons
As can be seen from tables 3 and 4, compared with the model group, the traditional Chinese medicine compositions prepared in examples 1 to 6 can reduce the temperature and change the blood leukocytes, but the changes are not obvious, the temperature and the blood leukocytes in comparative examples 1 to 3 do not change obviously compared with the model group, and the body temperature of the traditional Chinese medicine composition and the body temperature of the positive medicine group in example 7 are reduced to different degrees after administration for 1 hour, 2 hours and 4 hours; the high dose and positive drug group had significant changes in blood leukocytes after 4 hours of administration. The result shows that the traditional Chinese medicine composition prepared in example 7 has a strong inhibition effect on mouse fever caused by 2, 4-dinitrophenol.
(3) Antipyretic effect of traditional Chinese medicine composition on rabbit fever caused by 2, 4-dinitrophenol
In order to further prove that the traditional Chinese medicine composition prepared in example 7 has a better antipyretic effect, a verification test is carried out.
60 healthy rabbits are selected, the male and female parts of the rabbits are respectively in the weight of 2.0 +/-0.3 kg, and the experimental rabbits are 20: 00 begins, fasting does not prohibit water. The test pieces were randomly divided into six groups, namely a blank control group, a model group, a high dose group (1.7g/kg) in example 7, a medium dose group (0.85g/kg) in example 7, a low dose group (0.43g/kg) in example 7 and a positive drug control group (0.85g/kg), and 10 pieces of test pieces were added to each group.
The rabbits of each group were administered the test drug by gavage twice daily for 3 consecutive days. Wherein the medium dose is equivalent to the clinical treatment dose, and the blank control group is administered with the same volume of physiological saline. Except for the blank control group, each group was injected subcutaneously with 2, 4-dinitrophenol 25mg/kg 1 hour after the last administration. The body temperature of the rabbits was measured at 1h, 2h, and 4h after the injection, and the total number of blood leukocytes was measured at 4 hours. The test results are shown in Table 5.
TABLE 5 influence of Chinese medicinal composition on body temperature and blood leukocyte of 2, 4-dinitrophenol-pyrogenic rabbit: (
n＝10)
P <0.05, P <0.01, P <0.001 and model group comparisons
As can be seen from table 5, compared with the model group, the body temperatures of the traditional Chinese medicine composition, the high-dose group and the positive medicine group prepared in example 7 were reduced to different degrees at each time point after the model was made, and the blood leukocytes of the traditional Chinese medicine composition, the high-dose group and the positive medicine group prepared in example 7 were reduced to different degrees at 4 hours after the administration. The results show that the traditional Chinese medicine composition with medium and high dosage prepared in the embodiment 7 has strong inhibition effect on rabbit fever caused by 2, 4-dinitrophenol and has certain anti-inflammatory effect.
The above experiments show that the Chinese medicinal composition prepared in example 7 has the best therapeutic effect, so the following experiments are all carried out by using the Chinese medicinal composition prepared in example 7.
(4) A mouse acute pancreatitis model caused by intraperitoneal injection of L-arginine is adopted, and the treatment effect of the traditional Chinese medicine composition on the mouse acute pancreatitis is observed
Taking healthy mice, half of each male and female, 60 mice in total, and 20: 00 begins, fasting does not prohibit water. During the test, the mice are randomly divided into six groups, namely a blank control group, a model group, a high-dose group (4.5g/kg) of the traditional Chinese medicine composition prepared in example 7, a medium-dose group (2.25g/kg) of the traditional Chinese medicine composition prepared in example 7, a low-dose group (1.12g/kg) of the traditional Chinese medicine composition prepared in example 7 and a positive-drug group (2.25g/kg), wherein each group comprises 10 mice.
Each group of mice was gavaged with the test drug twice daily for 7 consecutive days. Wherein the medium dose is equivalent to the clinical treatment dose, and the blank control group is administered with the same volume of physiological saline. And (3) carrying out single intraperitoneal injection of 5g/Kg (weight) of 50% L-arginine physiological saline solution from day 7, re-administering once at the same dose after one hour, continuously intragastrically administering the test medicament, killing the animal at 72 hours, picking the pancreas, fixing by 10% formalin, carrying out pathological examination, and observing the pathological change condition of the pancreas of the mouse. The test result is shown in pathological picture (x 40).
As can be seen from fig. 2:
panel a2 is a blank control: the pancreatic tissue structure and the lobular outline are clear, the staining is uniform, the acinar lobules are complete, pancreatic ducts and blood vessels can be seen in the connective tissue between the lobules, and slight edema and a small amount of inflammatory cells in interstitial areas are occasionally seen.
Fig. b2 is a model set: it can be seen that there is a large amount of inflammatory cell infiltration in the regions around the pancreatic interstitium, acinus, pancreatic duct and lobule, and a large amount of light red myxedema fluid is scattered, the pancreatic duct and acinus morphological structure have different degrees of hemorrhage and necrosis, and a large amount of vacuoles of lobules, acinus and interstitium are formed.
Panel c2 is a group of positive drugs: the pancreatic tissue is basically normal in shape and structure, the lobules are clear in outline, the acini are complete, pancreatic ducts and blood vessels can be seen in the connective tissue between the lobules, and slight edema and a small amount of inflammatory cells in interstitial regions are occasionally seen.
Panel d2 is the high dose group: the morphological structures of the lobular outline, the acinus, the pancreatic duct and the lobules are basically normal, a small amount of infiltrating inflammatory cells still exist in the connective tissues of the surrounding area and the lobules, and slight edema of pancreatic ducts and interstitial areas is occasionally seen.
Panel e2 is the medium dose group: the hemorrhage and necrosis of pancreatic duct and acinus are recovered, and lobules, acinus and interstitial vacuole are reduced.
Panel f2 is the low dose group: there is still a varying degree of inflammatory cell infiltration in the connective tissue between the interstitial, periacinar, pancreatic duct and perilobular regions of the pancreas, slight edema in the acinar, pancreatic duct and interstitial regions, improved bleeding and necrosis of the pancreatic ducts and acini, and a reduction in the lobules, acini and interstitial vacuoles.
The pathological examination results of the pancreas of the mouse show that the traditional Chinese medicine composition prepared in example 7 has a certain effect of resisting acute pancreatitis of the mouse.
(5) The effect of the Chinese medicinal composition on the small intestine movement of the mice was observed by a method for measuring the length of the small intestine, which is specifically shown in table 6 below.
The experimental method comprises the following steps: taking 50 healthy mice, half of each male and female, and 20: 00 begins, fasting does not prohibit water. During the test, the mice are randomly divided into five groups, namely a blank control group, a high-dose group (4.5g/kg), a medium-dose group (2.25g/kg), a low-dose group (1.12g/kg) and a positive drug group (2.25g/kg), of the traditional Chinese medicine composition prepared in example 7, and each group contains 10 mice.
Each group of mice was administered the test drug by gavage twice daily for 3 consecutive days. Wherein the medium dose is equivalent to the clinical treatment dose, and the blank control group is administered with the same volume of physiological saline. The test drug containing 5% of activated carbon powder and 10% of gum arabic was administered to each last administration group, animals were sacrificed 1 hour after administration, dissected, and the duodenum was taken out to the small intestine of the cecal section, the length was measured, and the advancing distance of the drug in the small intestine was recorded.
TABLE 6 Effect of Chinese medicinal composition on intestinal motility of mice: (
n＝10)
P <0.05, P <0.01 compared to blank control
As can be seen from the test data in table 6 above, the Chinese medicinal composition prepared in example 7 in the dosage group (2.25g/kg) and the high dosage group (4.5g/kg) all increase the propelling distance and propelling rate of the carbon powder in the small intestine to different extents.
(6) By adopting an intraperitoneal acetic acid injection method, a mouse pain model is established, and the influence of the traditional Chinese medicine composition on the analgesia effect of the acetic acid-induced writhing reaction of the mouse is observed
The experimental method comprises the following steps: taking healthy mice, half of each male and female, 50 mice in total, weighing 20 +/-2 g, and 20: 00 begins, fasting does not prohibit water. During the test, the mice are randomly divided into five groups, namely a blank control group, a high-dose group (4.5g/kg) of the traditional Chinese medicine composition prepared in example 7, a medium-dose group (2.25g/kg) of the traditional Chinese medicine composition prepared in example 7, a low-dose group (1.12g/kg) of the traditional Chinese medicine composition prepared in example 7 and a positive-dose group (2.25g/kg), and 10 mice in each group.
Each group of mice was administered the test drug by gavage twice daily for 3 consecutive days. Experimental mice 20: 00 begins, fasting does not prohibit water. Wherein the medium dose is equivalent to the clinical treatment dose, and the blank control group is administered with the same volume of physiological saline. After 1 hour of the last administration, each mouse was intraperitoneally injected with 0.6% acetic acid (0.1mL/10g of body weight), the time of occurrence of writhing, the number of times of writhing, and the time of ending of writhing of each group of mice were observed within 30 minutes, and the analgesic rate of each group was calculated by comparing with that of a blank control group, as shown in table 7 below.
TABLE 7 analgesic effect of Chinese medicinal composition on acetic acid-induced writhing response in mice: (
n＝10)
P <0.05, P <0.01, P <0.001 compared to the blank control group
According to the detection data in table 7 above, the pain latency of the mice in the dosage group (2.25g/kg) and the high dosage group (4.5g/kg) of the traditional Chinese medicine composition prepared in example 7 is prolonged to different degrees, the number of writhing is significantly reduced, and the time for ending writhing is reduced to different degrees.
(7) A rat thrombus model is established by adopting a polyethylene tube inserted into common carotid artery-external jugular vein blood flow bypass method, and the influence of the traditional Chinese medicine composition prepared in the example 7 on the mouse common carotid artery-external jugular vein bypass thrombus is observed
The experimental method comprises the following steps:
taking 50 healthy rats with half weight of male and female, and 200 +/-20 g of body weight, wherein the experimental rat is 20: 00 begins, fasting does not prohibit water. During the test, rats are randomly divided into five groups, namely a blank control group, a high dose group (3.2g/kg), a medium dose group (1.6g/kg), a low dose group (0.8g/kg) and a positive drug group (1.6g/kg), and 10 rats are in each group.
Each group of rats was gavaged with the test drug twice daily for 3 consecutive days. Wherein the medium dose is equivalent to the clinical treatment dose, and the blank control group is administered with the same volume of physiological saline. After the last administration for 1 hour, 30mg/kg sodium pentobarbital is used for abdominal anesthesia, polyethylene tubes filled with heparin sodium solution are respectively inserted into the right common carotid artery and the left external jugular vein blood, after the operation is finished, the blood flow is opened after 5 minutes, the blood flow is interrupted after 15 minutes, the silk thread is rapidly taken out and weighed, and the difference between the total weight and the weight of the silk thread is the wet weight of the thrombus, which is specifically shown in the following table 8;
inhibition rate ═ control thrombus weight-administration group thrombus weight)/control thrombus weight × 100%
TABLE 8 influence of Chinese medicinal composition on thrombosis of common carotid artery-external jugular vein by blood flow bypass method: (
n＝10)
P <0.05, P <0.01 compared to blank control
As can be seen from Table 8, the weight average of thrombus was significantly decreased in the medium and high dose groups and the positive drug group, compared with the blank control group. The result shows that the traditional Chinese medicine composition prepared in the example 7 can obviously reduce the wet weight of the thrombus of the mouse and has obvious blood activating effect.
(8) Influence of traditional Chinese medicine composition on rat toe swelling caused by carrageenan
Taking healthy rats with half of each sex and 200 +/-20 g of body weight, and taking 50 rats in total, wherein the experimental rats have a weight ratio of 20: 00 begins, fasting does not prohibit water. During the test, mice are randomly divided into five groups, namely a model group, a high-dose group (3.2g/kg) of the traditional Chinese medicine composition prepared in example 7, a medium-dose group (1.6g/kg) of the traditional Chinese medicine composition prepared in example 7, a low-dose group (0.8g/kg) of the traditional Chinese medicine composition prepared in example 7 and a positive medicine group (1.6g/kg), wherein each group comprises 10 mice.
Each group of mice was gavaged with the test drug twice daily for 3 consecutive days. Where the medium dose was comparable to the clinical treatment dose, the model group was given an equal volume of saline. The mice were injected with 0.1mL of 1% carrageenan physiological saline suspension 1 hour after the last administration to cause inflammation, and the toe swelling degree of the mice was measured 1 hour, 2 hours, 3 hours, 4 hours, 5 hours and 6 hours after the injection. The test results are shown in Table 9.
TABLE 9 Effect of Chinese medicinal composition on carrageenan-induced swelling of toes in rats: (
n＝10)
P <0.05, P <0.01, P <0.001 and model group comparisons
As can be seen from table 9, the toe swelling was decreased in the high dose group and the positive drug group in the traditional Chinese medicine composition prepared in example 7 at various time points compared with the model group. The results show that the traditional Chinese medicine composition prepared in example 7 has a certain inhibition effect on the swelling of toes of rats caused by carrageenan.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. A traditional Chinese medicine composition for treating pancreatitis and pancreatic pseudocyst is characterized in that: the traditional Chinese medicine composition comprises effective components and medically acceptable auxiliary materials,
the effective components comprise: 320g of bupleurum, 100 g of scutellaria, 150 g of white peony, 300g of costus root, 150 g of vinegar rhizoma corydalis, 350g of gardenia, 400g of rhubarb and 100 g of mirabilite;
the preparation method of the traditional Chinese medicine composition comprises the following steps:
(1) removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae, and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powders of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 10-20 deg.C for 3 hr under ultrasonic condition, and filtering to obtain filtrate 1 and soaked substance 1; quickly placing the soaked substance 1 in water of 70-80 ℃ for soaking for 3 hours, and filtering to obtain filtrate 2 and soaked substance 2; rapidly soaking the soaked substance 2 in 10-20 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; rapidly soaking the soaked substance 3 at 70-80 deg.C for 1 hr, and filtering to obtain filtrate 4 and soaked substance 4; mixing the filtrates 1-4 to obtain mixed solution;
(2) pulverizing Natrii sulfas with a pulverizer, and sieving with 200 mesh sieve to obtain fine powder;
(3) adding 8-10 times of water into the soaked matter 4 in the step (1), decocting for 1-2 hours, and filtering to obtain medicine residue 1 and an extracted medicine liquid 1;
(4) adding 6-8 times of water into the residue 1 obtained in the step (3), boiling, adding the rhubarb fine powder, decocting for 1 hour, and filtering to obtain an extracted liquid medicine 2;
(5) combining the combined solution obtained in the steps (1), (3) and (4), the extracted liquid medicine 1 and the extracted liquid medicine 2, and concentrating the mixture to form thick paste with the relative density of more than 1.30-1.33;
(6) adding auxiliary materials and synergistic components into the thick paste obtained in the step (5), uniformly mixing, and drying at the temperature of below 80 ℃ to obtain dry paste;
(7) mixing the dry paste obtained in step (6) with the mirabilite fine powder obtained in step (2), pulverizing into fine powder, sieving with a 100-mesh sieve, adding adjuvants, mixing, granulating with 80% ethanol, drying, and grading to obtain Chinese medicinal composition;
the mass ratio of the volume of the added water to the fine medicine powder, the soaked substance 1, the soaked substance 2 and the soaked substance 3 in the step (1) is 1mL:1 g.
2. The traditional Chinese medicine composition according to claim 1, characterized in that: the effective components comprise: 200-300g of bupleurum, 120-200g of scutellaria, 180-250g of white peony root, 180-250g of costustoot, 150-250g of vinegar rhizoma corydalis, 220-320g of gardenia, 300-380g of rhubarb and 120-180g of mirabilite.
3. The traditional Chinese medicine composition according to claim 1, characterized in that: the active ingredients comprise 300g of bupleurum root 250-.
4. The traditional Chinese medicine composition according to claim 3, wherein: the effective components comprise 250g of radix bupleuri, 200g of radix scutellariae, 250g of radix paeoniae alba, 250g of radix aucklandiae, 250g of vinegar rhizoma corydalis, 250g of fructus gardeniae, 330g of rheum officinale and 167g of mirabilite.
5. The traditional Chinese medicine composition according to claim 1, characterized in that: the preparation method comprises the following steps (1):
removing impurities from bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis, fructus Gardeniae and radix et rhizoma Rhei, cleaning, air drying, pulverizing, and sieving with 200 mesh sieve to obtain fine powder; mixing the obtained fine powder of bupleuri radix, Scutellariae radix, radix Paeoniae alba, radix aucklandiae, rhizoma corydalis and fructus Gardeniae, adding water, soaking at 15 deg.C for 3 hr under ultrasonic treatment, filtering to obtain filtrate 1 and soak 1, rapidly soaking soak 1 in 80 deg.C water for 3 hr, and filtering to obtain filtrate 2 and soak 2; rapidly soaking the soaked substance 2 in 10 deg.C water for 1 hr without cooling, and filtering to obtain filtrate 3 and soaked substance 3; rapidly soaking the soaked substance 3 in 75 deg.C water for 1 hr, filtering to obtain filtrate 4 and soaked substance 4, and mixing filtrates 1-4 to obtain mixed solution;
the mass ratio of the volume of the added water to the fine medicine powder, the soaked substance 1, the soaked substance 2 and the soaked substance 3 is 1mL:1 g.
6. The traditional Chinese medicine composition according to claim 1, characterized in that: the auxiliary materials are one or more of a filling agent, a wetting agent, an adhesive, a disintegrating agent and a lubricating agent.
7. The traditional Chinese medicine composition according to claim 1, wherein: the traditional Chinese medicine composition also contains synergistic components, and the weight of the synergistic components is 1-3% of the effective components.
8. The traditional Chinese medicine composition according to claim 7, wherein: the synergistic component is one or more of L-arginine, vitamin E and menthol.
9. The traditional Chinese medicine composition according to claim 8, wherein: the synergistic components are vitamin E and L-arginine with the weight ratio of 2-5: 1.
10. The use of the composition of claim 1 in the preparation of a medicament for the treatment of acute or chronic pancreatitis and pseudocyst of the pancreas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010791502.6A CN111700938A (en) | 2020-08-07 | 2020-08-07 | A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010791502.6A CN111700938A (en) | 2020-08-07 | 2020-08-07 | A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111700938A true CN111700938A (en) | 2020-09-25 |
Family
ID=72546941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010791502.6A Pending CN111700938A (en) | 2020-08-07 | 2020-08-07 | A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111700938A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040576A (en) * | 2022-06-30 | 2022-09-13 | 四川大学华西医院 | Pharmaceutical composition for treating acute pancreatitis |
| CN116650584A (en) * | 2023-07-06 | 2023-08-29 | 大连医科大学附属第一医院 | Traditional Chinese medicine composition with effects of relaxing bowels, relieving pain, eliminating turbid pathogen and reducing lipid as well as preparation method and application thereof |
-
2020
- 2020-08-07 CN CN202010791502.6A patent/CN111700938A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 宋胜江等: "清胰汤对实验性重症胰腺炎大鼠炎症介质的影响", 《福建中医药》 * |
| 张桂信等: "清胰汤对大鼠急性坏死性胰腺炎时胰腺腺泡细胞凋亡的影响", 《中国中西医结合外科杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040576A (en) * | 2022-06-30 | 2022-09-13 | 四川大学华西医院 | Pharmaceutical composition for treating acute pancreatitis |
| CN115040576B (en) * | 2022-06-30 | 2023-10-27 | 四川大学华西医院 | Pharmaceutical composition for treating acute pancreatitis |
| CN116650584A (en) * | 2023-07-06 | 2023-08-29 | 大连医科大学附属第一医院 | Traditional Chinese medicine composition with effects of relaxing bowels, relieving pain, eliminating turbid pathogen and reducing lipid as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102085252A (en) | Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof | |
| CN102266508B (en) | Chinese medicinal composition for treating drying syndrome and preparation method and application thereof | |
| CN111700938A (en) | A Chinese medicinal composition for treating pancreatitis and pancreatic pseudocyst | |
| CN101417070B (en) | Medicine combination for treating coprostasis and preparation method thereof | |
| CN102961508A (en) | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN104147536A (en) | Medicine composition for treating haemorrhoids and preparation method thereof | |
| CN108543044B (en) | Combined medicine for treating acne and application thereof | |
| CN101690787B (en) | Traditional Chinese medicine for treating chronic gastritis and gastric ulcer | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN101919985A (en) | Drug for treating fatty liver and preparation method and use thereof | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN101099775A (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN100408062C (en) | Medicine for promoting blood circulation and relaxing the bowels and its preparing method | |
| CN109464565A (en) | A kind of Chinese medicine composition and its preparation for treating chest impediment and cardialgia | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof | |
| CN108420913A (en) | A kind of Chinese medicine composition and preparation method thereof for treating asthma | |
| CN113694136B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN100574796C (en) | Treat cardiopathic medicine and preparation method thereof | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN1970017A (en) | Medicament for treating ulcerative colitis and preparation process thereof | |
| CN114129693A (en) | Composition for treating cancer and preparation method and application thereof | |
| CN105396107A (en) | Traditional Chinese medicine composition for curing gastroenteritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |